Skip to main content
. Author manuscript; available in PMC: 2015 Jul 14.
Published in final edited form as: Cancer Cell. 2014 Jul 14;26(1):11–13. doi: 10.1016/j.ccr.2014.06.023

Figure 1.

Figure 1

B cell Receptor Signaling in malignant B cells.

Chronic active BCR signaling is shown. Ibrutinib is shown to inhibit BTK. Red asterisks denote signaling effectors that are the target of ibrutinib resistance mutations in CLL patients.